Astrana Health (ASTH) Financials

$32.39 -0.10 (-0.31%)

Closing price 05/5/2025 04:00 PM Eastern

Extended Trading

$32.37 -0.02 (-0.06%)

As of 04:19 AM Eastern

Annual Income Statements for Astrana Health

This table shows Astrana Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	1/31/2014	3/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-4.56	-1.80	11	26	11	14	38	69	45	61	43
Consolidated Net Income / (Loss)	-4.56	-1.35	10	46	60	18	122	46	46	58	50
Net Income / (Loss) Continuing Operations	-4.56	-1.35	10	46	60	18	122	46	46	58	50
Total Pre-Tax Income	-4.54	-1.18	19	50	83	26	178	78	87	90	81
Total Operating Income	-3.91	-0.69	12	35	88	32	81	98	104	85	89
Total Gross Profit	1.41	11	51	83	155	94	148	178	199	215	271
Total Revenue	10	33	306	356	520	561	687	774	1,144	1,387	2,035
Operating Revenue	10	33	282	356	520	561	687	774	1,144	1,387	2,035
Total Cost of Revenue	9.08	22	255	273	365	466	539	596	945	1,172	1,763
Operating Cost of Revenue	9.08	22	255	273	361	468	539	596	945	1,172	1,763
Total Operating Expenses	5.32	12	39	48	66	62	67	80	95	130	182
Selling, General & Admin Expense	5.29	11	21	26	43	41	49	62	78	113	154
Depreciation Expense	0.03	0.33	18	19	19	18	18	18	18	18	28
Total Other Income / (Expense), net	-0.63	-0.49	7.15	15	-5.81	-6.58	98	-20	-18	5.23	-8.53
Interest Expense	0.68	1.33	0.06	0.08	0.56	4.73	9.50	5.39	7.92	16	33
Interest & Investment Income	-	-	5.25	14	-6.87	-4.88	106	-0.54	7.60	20	19
Other Income / (Expense), net	0.05	0.84	1.96	1.05	1.62	3.03	1.08	-14	-17	1.54	5.61
Income Tax Expense	0.02	0.16	8.82	3.89	22	8.17	56	32	41	32	31
Net Income / (Loss) Attributable to Noncontrolling Interest	-	0.45	-1.43	20	49	3.56	84	-23	0.57	-2.87	6.78
Basic Earnings per Share	($0.12)	($0.37)	$0.46	$1.01	$0.33	$0.41	$1.03	$1.57	$1.00	$1.30	$0.91
Weighted Average Basic Shares Outstanding	49.13M	4.89M	24.67M	25.53M	32.89M	52.80M	54.59M	55.96M	57.44M	55.42M	56.25M
Diluted Earnings per Share	($0.12)	($0.37)	$0.41	$0.90	$0.29	$0.39	$1.01	$1.52	$0.99	$1.29	$0.90
Weighted Average Diluted Shares Outstanding	49.13M	4.89M	27.97M	28.66M	37.91M	52.80M	54.59M	55.96M	57.44M	55.42M	56.25M
Weighted Average Basic & Diluted Shares Outstanding	36.66M	4.89M	5.21M	6.95M	32.80M	52.80M	54.59M	55.96M	57.44M	55.42M	56.25M

This table shows Astrana Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Net Income / (Loss) Attributable to Common Shareholders	23	-3.73	13	13	22	15	19	16
Consolidated Net Income / (Loss)	24	-0.88	12	17	28	17	22	19
Net Income / (Loss) Continuing Operations	24	-0.88	12	17	28	17	22	19
Total Pre-Tax Income	41	10	19	31	38	24	32	27
Total Operating Income	50	13	22	27	39	30	30	28
Total Gross Profit	76	41	48	55	73	74	73	73
Total Revenue	317	294	337	348	348	404	486	479
Operating Revenue	317	294	337	348	348	404	486	479
Total Cost of Revenue	241	253	289	293	275	330	413	405
Operating Cost of Revenue	241	253	289	293	275	330	413	405
Total Operating Expenses	26	29	25	28	34	44	43	45
Selling, General & Admin Expense	21	24	21	24	29	39	36	38
Depreciation Expense	4.75	4.06	4.29	4.25	4.31	5.10	7.44	7.26
Total Other Income / (Expense), net	-8.83	-2.13	-2.96	4.46	-1.07	-6.14	1.83	-1.61
Interest Expense	2.42	2.57	3.27	3.63	3.78	7.59	8.59	8.86
Interest & Investment Income	1.68	2.51	5.49	6.05	1.18	4.63	4.42	5.13
Other Income / (Expense), net	-8.08	-2.07	-5.19	2.04	1.53	-3.18	6.00	2.11
Income Tax Expense	17	11	6.92	14	10	7.14	10	7.83
Net Income / (Loss) Attributable to Noncontrolling Interest	0.71	2.85	-0.64	4.31	5.91	2.03	2.70	2.89
Basic Earnings per Share	$0.52	($0.10)	$0.28	$0.28	$0.47	$0.31	$0.40	$0.34
Weighted Average Basic Shares Outstanding	44.95M	57.44M	57.55M	57.56M	58.28M	56.03M	56.21M	56.25M
Diluted Earnings per Share	$0.50	($0.07)	$0.28	$0.28	$0.47	$0.31	$0.40	$0.33
Weighted Average Diluted Shares Outstanding	46.15M	57.44M	57.55M	57.56M	58.28M	56.03M	56.21M	56.25M
Weighted Average Basic & Diluted Shares Outstanding	56.72M	57.44M	57.55M	57.56M	58.28M	56.03M	56.21M	56.25M

This table details how cash moves in and out of Astrana Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	1/31/2014	3/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	0.27	-1.82	-4.19	64	-11	-3.63	90	39	55	6.13	-5.05
Net Cash From Operating Activities	-1.48	-0.27	22	52	25	14	46	70	82	68	52
Net Cash From Continuing Operating Activities	-1.48	-0.27	22	52	25	14	46	70	82	68	52
Net Income / (Loss) Continuing Operations	-4.56	-1.35	10	46	60	18	122	46	46	58	50
Consolidated Net Income / (Loss)	-4.56	-1.35	10	46	60	18	122	46	46	58	50
Depreciation Expense	0.03	0.33	18	19	19	18	18	18	18	18	28
Amortization Expense	0.39	0.52	-	-	0.00	0.47	1.35	1.08	0.94	1.06	1.83
Non-Cash Adjustments To Reconcile Net Income	2.14	0.50	0.99	-6.49	-4.18	9.31	-100	31	38	28	37
Changes in Operating Assets and Liabilities, net	0.52	-0.28	-7.21	-6.57	-50	-32	4.08	-25	-20	-36	-64
Net Cash From Investing Activities	-0.27	-3.20	-8.96	27	-25	-181	95	17	-7.11	-66	-192
Net Cash From Continuing Investing Activities	-0.27	-3.20	-8.96	27	-25	-181	95	17	-7.11	-66	-192
Purchase of Property, Plant & Equipment	-0.02	-0.04	-3.31	-2.08	-1.17	-1.04	-1.16	-19	-23	-29	-8.03
Acquisitions	-0.25	-3.36	-2.44	0.00	-17	-53	-21	-16	-16	-6.84	-152
Purchase of Investments	-	-	-5.21	-10	-7.91	-127	-1.94	-28	-1.85	-6.15	-6.52
Sale and/or Maturity of Investments	-	0.44	2.00	1.44	0.61	0.24	67	68	32	0.49	0.12
Other Investing Activities, net	-	-0.24	0.00	0.23	-	0.00	0.00	5.93	1.96	-24	-26
Net Cash From Financing Activities	2.03	1.66	-17	-15	-11	163	-52	-48	-20	3.42	135
Net Cash From Continuing Financing Activities	2.03	1.66	-17	-15	-11	163	-52	-48	-20	3.42	135
Repayment of Debt	-1.50	-1.47	-2.26	-9.10	-0.59	-55	-9.61	-239	-4.43	-205	-19
Repurchase of Common Equity	-	-	-0.52	-3.18	-5.05	-13	-0.54	-6.47	-9.25	-14	-0.94
Payment of Dividends	-0.24	-0.60	-26	-10	-18	-62	-52	-33	-19	-62	-3.93
Issuance of Debt	3.03	3.00	0.00	5.00	8.00	290	0.00	181	3.60	285	172
Issuance of Common Equity	0.73	0.73	11	2.16	0.20	0.00	0.00	40	0.00	0.00	0.27
Other Financing Activities, net	0.00	-0.00	0.26	0.59	4.00	3.12	11	9.06	8.63	0.52	-13
Cash Interest Paid	0.25	0.77	0.06	0.05	0.46	4.26	8.51	4.16	6.67	14	30
Cash Income Taxes Paid	0.02	0.03	29	24	24	20	62	37	47	57	44

This table details how cash moves in and out of Astrana Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024
Net Change in Cash & Equivalents	-50	104	-13	20	-20	41
Net Cash From Operating Activities	-36	85	7.72	26	15	5.98
Net Cash From Continuing Operating Activities	-36	85	7.72	26	15	5.98
Net Income / (Loss) Continuing Operations	24	-0.88	12	17	28	17
Consolidated Net Income / (Loss)	24	-0.88	12	17	28	17
Depreciation Expense	4.76	4.06	4.29	4.25	4.31	5.10
Amortization Expense	0.23	0.24	0.24	0.24	0.24	0.46
Non-Cash Adjustments To Reconcile Net Income	12	8.93	8.73	4.46	5.98	4.09
Changes in Operating Assets and Liabilities, net	-76	73	-18	-0.63	-23	-21
Net Cash From Investing Activities	-8.09	13	-14	-5.19	-35	-71
Net Cash From Continuing Investing Activities	-8.09	13	-14	-5.19	-35	-71
Purchase of Property, Plant & Equipment	-3.21	-0.89	-6.03	-11	-4.11	-0.37
Acquisitions	-4.76	-11	-0.33	0.35	-5.02	-51
Purchase of Investments	-	-0.10	-1.00	-3.02	-25	-20
Sale and/or Maturity of Investments	-0.02	25	2.14	0.00	0.06	0.01
Other Investing Activities, net	-0.10	-0.32	-8.82	8.82	-0.70	0.00
Net Cash From Financing Activities	-6.25	5.87	-7.10	-0.96	-0.51	106
Net Cash From Continuing Financing Activities	-6.25	5.87	-7.10	-0.96	-0.51	106
Repayment of Debt	-3.65	-0.30	-0.31	-0.31	-0.35	-3.68
Repurchase of Common Equity	-0.17	0.40	-9.54	-	-0.15	0.00
Payment of Dividends	-0.09	-6.03	-0.12	-0.72	-1.42	0.03
Issuance of Debt	0.75	1.61	1.62	0.12	1.42	110
Other Financing Activities, net	-3.09	10	1.25	-0.05	-	0.00
Cash Interest Paid	2.16	2.29	2.99	3.27	3.41	6.43
Cash Income Taxes Paid	20	5.50	0.00	-	-	0.19

This table presents Astrana Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	3/31/2014	3/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	9.48	15	350	491	513	729	817	867	966	933	1,355
Total Current Assets	8.43	9.85	81	144	173	329	339	404	428	462	638
Cash & Equivalents	6.83	5.01	55	100	107	103	193	233	288	294	288
Short-Term Investments	-	-	1.05	1.14	1.13	117	68	53	5.57	2.50	2.38
Accounts Receivable	1.53	4.05	22	20	57	76	61	90	117	137	305
Prepaid Expenses	0.04	0.79	1.85	5.14	7.39	10	17	19	15	17	23
Current Deferred & Refundable Income Taxes	-	-	-	-	-	-	-	-	0.00	11	19
Plant, Property, & Equipment, net	0.09	0.58	10	14	13	12	30	53	109	7.17	14
Total Noncurrent Assets	0.96	4.56	258	333	327	388	449	410	430	465	702
Long-Term Investments	-	-	35	22	35	29	80	43	43	32	48
Noncurrent Note & Lease Receivables	-	-	5.20	15	18	0.00	4.63	0.57	0.00	26	51
Goodwill	0.49	2.17	103	190	186	239	239	246	269	279	419
Intangible Assets	0.06	1.38	108	104	87	103	87	83	77	72	118
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	-	-	16	16	16	16
Other Noncurrent Operating Assets	0.04	0.75	6.94	2.38	1.95	17	38	21	25	40	49
Total Liabilities & Shareholders' Equity	9.48	15	350	491	513	729	817	867	966	933	1,355
Total Liabilities	11	16	100	154	106	368	372	357	408	523	841
Total Current Liabilities	2.44	5.97	51	110	72	105	115	115	149	219	366
Short-Term Debt	-	1.04	0.10	0.61	0.04	9.50	11	0.78	0.62	20	9.38
Accounts Payable	1.45	3.34	9.13	20	27	29	46	54	58	68	114
Dividends Payable	-	-	-	-	0.00	0.27	0.49	0.56	0.66	0.64	0.64
Other Current Liabilities	1.00	1.59	39	85	34	62	54	59	85	131	241
Total Noncurrent Liabilities	8.66	10	49	45	34	262	257	242	259	304	475
Long-Term Debt	6.31	7.69	-	-	0.00	232	230	183	203	259	425
Noncurrent Deferred & Payable Income Tax Liabilities	0.00	0.17	47	25	20	18	11	30	14	4.07	4.56
Other Noncurrent Operating Liabilities	2.35	2.14	2.00	19	1.19	12	16	29	41	41	45
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	0.00	163	172	225	169	114	57	14	-206	-203
Total Equity & Noncontrolling Interests	-1.62	-0.99	88	164	182	192	331	454	544	617	717
Total Preferred & Common Equity	-1.22	-2.82	87	160	181	192	331	448	543	614	713
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-1.22	-2.82	87	160	181	192	331	448	543	614	713
Common Stock	15	17	88	158	163	160	261	311	360	371	426
Retained Earnings	-16	-19	-0.77	1.73	18	32	70	137	182	243	286
Noncontrolling Interest	-0.41	1.83	0.38	4.24	1.00	0.79	0.09	5.94	1.75	2.43	4.01

This table presents Astrana Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	943	999	1,027	1,073	1,226	1,252	1,285
Total Current Assets	444	455	465	476	539	570	597
Cash & Equivalents	184	275	294	274	335	325	348
Short-Term Investments	33	4.11	3.79	3.02	2.49	2.38	2.35
Accounts Receivable	202	153	151	184	184	203	210
Prepaid Expenses	12	22	15	14	17	17	21
Current Deferred & Refundable Income Taxes	12	0.00	-	-	0.00	22	16
Plant, Property, & Equipment, net	104	113	124	129	7.99	10	12
Total Noncurrent Assets	396	431	438	468	679	672	676
Long-Term Investments	40	44	49	47	42	42	44
Noncurrent Note & Lease Receivables	2.64	-	-	25	47	49	55
Goodwill	257	269	274	276	410	410	410
Intangible Assets	73	78	74	74	120	116	109
Noncurrent Deferred & Refundable Income Taxes	-	16	16	16	16	16	16
Other Noncurrent Operating Assets	22	24	25	30	44	39	43
Total Liabilities & Shareholders' Equity	943	999	1,027	1,073	1,226	1,252	1,285
Total Liabilities	390	434	444	458	774	774	778
Total Current Liabilities	156	173	186	203	355	310	313
Short-Term Debt	3.16	0.62	2.63	2.99	21	17	15
Accounts Payable	54	58	59	59	154	103	101
Dividends Payable	0.56	0.66	0.64	0.64	0.64	0.64	0.64
Other Current Liabilities	99	102	104	110	174	189	196
Total Noncurrent Liabilities	234	260	258	255	419	464	465
Long-Term Debt	199	205	205	206	368	425	423
Noncurrent Deferred & Payable Income Tax Liabilities	4.70	14	12	12	3.76	3.25	2.86
Other Noncurrent Operating Liabilities	30	40	39	36	45	36	39
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	40	14	14	18	-206	-204	-203
Total Equity & Noncontrolling Interests	514	551	570	598	658	683	710
Total Preferred & Common Equity	510	548	566	594	653	679	705
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	510	548	566	594	653	679	705
Common Stock	315	353	357	363	396	402	411
Retained Earnings	195	196	209	231	258	277	293
Noncontrolling Interest	3.07	2.71	3.74	4.00	4.49	4.13	5.00

This table displays calculated financial ratios and metrics derived from Astrana Health's official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	1/31/2014	3/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	34.83%	214.66%	827.36%	16.48%	45.90%	7.83%	22.58%	12.62%	47.84%	21.19%	46.72%
EBITDA Growth	52.19%	129.06%	3,080.20%	74.02%	97.87%	-50.43%	86.85%	0.99%	3.07%	-0.43%	18.82%
EBIT Growth	51.56%	103.68%	19,084.99%	32.62%	148.83%	-60.63%	130.13%	2.58%	3.89%	-0.90%	10.22%
NOPAT Growth	-88.11%	82.24%	1,379.27%	421.06%	99.09%	-65.62%	148.41%	5.58%	-5.32%	-1.05%	1.32%
Net Income Growth	48.80%	70.43%	843.33%	357.34%	31.52%	-70.68%	590.79%	-62.28%	-0.68%	26.47%	-13.69%
EPS Growth	55.56%	-208.33%	421.62%	119.51%	-67.78%	34.48%	158.97%	50.50%	-34.87%	30.30%	-30.23%
Operating Cash Flow Growth	-2,650.56%	81.61%	16,318.40%	136.54%	-50.81%	-46.37%	237.62%	52.36%	16.77%	-16.93%	-23.49%
Free Cash Flow Firm Growth	90.63%	-6,701.33%	-5,571.54%	152.04%	-110.11%	-249.46%	216.38%	-32.14%	-127.22%	1,119.33%	-261.49%
Invested Capital Growth	-2,160.19%	197.12%	12,784.07%	-38.42%	40.75%	27.79%	-2.45%	4.31%	18.56%	-15.36%	68.92%
Revenue Q/Q Growth	8.25%	27.29%	631.54%	-33.70%	2.77%	14.77%	-0.29%	2.42%	9.48%	4.43%	0.00%
EBITDA Q/Q Growth	-29.17%	352.89%	1,396.82%	-38.61%	7.04%	19.56%	16.09%	-31.27%	42.07%	-8.92%	0.00%
EBIT Q/Q Growth	-22.94%	-93.55%	1,058.05%	-37.38%	8.93%	31.01%	21.27%	-35.68%	56.84%	-11.54%	0.00%
NOPAT Q/Q Growth	-20.94%	50.51%	282.58%	-4.87%	-9.62%	24.94%	19.67%	-26.57%	30.81%	-6.12%	0.00%
Net Income Q/Q Growth	-13.70%	34.04%	347.88%	17.53%	-27.49%	3.89%	12.90%	-43.33%	89.99%	1.38%	0.00%
EPS Q/Q Growth	-9.09%	17.78%	147.13%	-48.86%	-65.88%	254.55%	6.32%	-3.80%	-21.43%	34.38%	0.00%
Operating Cash Flow Q/Q Growth	-39.80%	-1,054.20%	896.00%	-13.70%	-46.19%	267.94%	-11.82%	-12.00%	647.48%	-49.03%	0.00%
Free Cash Flow Firm Q/Q Growth	96.30%	-331.51%	-27,207.32%	494.16%	92.23%	-7.00%	-14.58%	-26.13%	90.25%	114.81%	0.00%
Invested Capital Q/Q Growth	-2,850.14%	171.63%	5,565.79%	9,253.81%	0.64%	2.84%	9.41%	7.13%	-14.45%	-27.90%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	13.43%	33.11%	39.53%	23.26%	29.79%	16.80%	21.53%	22.97%	17.43%	15.50%	13.34%
EBITDA Margin	-32.78%	3.03%	20.76%	15.51%	21.03%	9.67%	14.74%	13.22%	9.21%	7.57%	6.13%
Operating Margin	-37.29%	-2.10%	7.64%	9.86%	17.01%	5.78%	11.72%	12.69%	9.11%	6.10%	4.39%
EBIT Margin	-36.82%	0.43%	8.92%	10.16%	17.32%	6.32%	11.87%	10.81%	7.60%	6.21%	4.67%
Profit (Net Income) Margin	-43.48%	-4.09%	6.55%	12.86%	11.59%	3.15%	17.77%	5.95%	4.00%	4.17%	2.45%
Tax Burden Percent	100.43%	113.83%	152.33%	92.18%	72.94%	68.39%	68.42%	59.24%	52.81%	64.39%	61.78%
Interest Burden Percent	117.59%	-832.50%	276.10%	137.36%	91.75%	72.89%	218.71%	92.91%	99.63%	104.28%	85.11%
Effective Tax Rate	0.00%	0.00%	46.81%	7.82%	27.06%	31.61%	31.58%	40.76%	47.19%	35.61%	38.22%
Return on Invested Capital (ROIC)	0.00%	0.00%	7.67%	12.55%	27.24%	7.03%	15.76%	16.49%	13.99%	13.82%	11.36%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-1.05%	1.34%	30.38%	13.60%	-109.33%	26.15%	20.60%	10.11%	-11.13%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.37%	-0.54%	-11.01%	-2.43%	14.53%	-6.85%	-5.44%	-1.89%	-0.56%
Return on Equity (ROE)	452.60%	103.16%	8.03%	12.01%	16.22%	4.60%	30.29%	9.64%	8.56%	11.94%	10.80%
Cash Return on Invested Capital (CROIC)	0.00%	-222.71%	-383.23%	60.10%	-6.62%	-17.37%	18.24%	12.27%	-2.99%	30.46%	-39.90%
Operating Return on Assets (OROA)	-60.76%	1.16%	14.95%	8.61%	17.95%	5.71%	10.55%	9.93%	9.48%	9.07%	8.30%
Return on Assets (ROA)	-71.76%	-11.01%	10.98%	10.90%	12.01%	2.85%	15.79%	5.47%	4.99%	6.09%	4.36%
Return on Common Equity (ROCE)	352.72%	159.19%	55,787.31%	5.06%	7.43%	2.23%	19.62%	7.85%	7.93%	14.24%	15.49%
Return on Equity Simple (ROE_SIMPLE)	375.19%	47.84%	11.49%	28.65%	33.38%	9.23%	36.90%	10.28%	8.43%	9.42%	7.01%
Net Operating Profit after Tax (NOPAT)	-2.74	-0.49	6.22	32	65	22	55	58	55	54	55
NOPAT Margin	-26.10%	-1.47%	4.06%	9.09%	12.41%	3.96%	8.02%	7.51%	4.81%	3.93%	2.71%
Net Nonoperating Expense Percent (NNEP)	-920.47%	67.86%	446.82%	11.22%	-3.14%	-6.57%	125.08%	-9.66%	-6.61%	3.72%	22.50%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	7.36%	6.09%	4.79%
Cost of Revenue to Revenue	86.57%	66.89%	166.55%	76.74%	70.21%	83.20%	78.47%	77.03%	82.57%	84.50%	86.66%
SG&A Expenses to Revenue	50.42%	34.20%	45.38%	7.37%	8.34%	7.40%	7.15%	8.02%	6.79%	8.12%	7.57%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	50.72%	35.21%	52.21%	13.40%	12.78%	11.02%	9.82%	10.28%	8.32%	9.40%	8.95%
Earnings before Interest and Taxes (EBIT)	-3.86	0.14	27	36	90	35	82	84	87	86	95
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-3.44	1.00	32	55	109	54	101	102	105	105	125
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.21	4.30	4.17	5.08	3.01	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	208.37	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.81	0.10	0.06	1.93	1.45	1.73	1.45	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	1.59	26.66	69.46	68.87	26.46	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	63.00%	3.75%	1.44%	1.45%	3.78%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	3.55	0.57	3.68	3.02	3.21	2.93	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.72	0.26	0.59	2.03	1.61	2.02	1.47	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	8.73	2.86	13.11	7.64	20.92	9.98	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	61.32	6.65	20.02	9.28	31.99	12.39	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	14.59	22.37	12.96	51.15	18.36	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	4.14	13.98	32.79	82.95	21.90	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	4.67	0.00	0.00	15.86	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-3.89	-8.82	0.13	0.00	0.00	0.67	0.54	0.36	0.37	0.68	0.85
Long-Term Debt to Equity	-3.89	-7.77	0.00	0.00	0.00	0.64	0.52	0.36	0.36	0.63	0.83
Financial Leverage	0.20	-0.97	-0.70	-0.41	-0.36	-0.18	-0.13	-0.26	-0.26	-0.19	0.05
Leverage Ratio	-6.31	-9.37	72.97	1.43	1.35	1.62	1.92	1.76	1.71	1.96	2.47
Compound Leverage Factor	-7.42	77.98	81.30	1.97	1.24	1.18	4.19	1.64	1.71	2.04	2.11
Debt to Total Capital	134.65%	112.79%	11.40%	0.36%	0.14%	40.10%	35.13%	26.46%	26.75%	40.40%	45.81%
Short-Term Debt to Total Capital	0.00%	13.41%	0.04%	0.18%	0.01%	1.58%	1.59%	0.11%	0.08%	2.83%	0.99%
Long-Term Debt to Total Capital	134.65%	99.38%	0.00%	0.18%	0.13%	38.52%	33.55%	26.34%	26.67%	37.57%	44.82%
Preferred Equity to Total Capital	0.00%	0.00%	233.70%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-8.71%	23.61%	230.16%	52.25%	55.53%	28.12%	16.66%	9.00%	2.10%	-29.52%	-20.93%
Common Equity to Total Capital	-25.94%	-36.41%	69.61%	47.39%	44.34%	31.78%	48.21%	64.55%	71.15%	89.12%	75.11%
Debt to EBITDA	-1.84	8.74	0.00	0.02	0.01	4.46	2.38	1.80	1.94	2.65	3.49
Net Debt to EBITDA	0.16	3.72	-0.27	-2.53	-1.31	-0.14	-0.99	-1.42	-1.25	-0.48	0.77
Long-Term Debt to EBITDA	-1.84	7.70	0.00	0.01	0.00	4.28	2.27	1.79	1.93	2.47	3.41
Debt to NOPAT	-2.30	-17.96	0.03	0.04	0.01	10.90	4.38	3.16	3.71	5.11	7.87
Net Debt to NOPAT	0.20	-7.64	-11.02	-4.31	-2.21	-0.34	-1.82	-2.50	-2.40	-0.92	1.73
Long-Term Debt to NOPAT	-2.30	-15.83	0.00	0.02	0.01	10.47	4.18	3.15	3.69	4.75	7.70
Altman Z-Score	-0.30	0.86	1.21	3.73	6.12	2.95	3.22	0.00	0.00	0.00	0.00
Noncontrolling Interest Sharing Ratio	22.07%	-54.31%	1,815.55%	57.88%	54.17%	51.53%	35.21%	18.50%	7.34%	-19.34%	-43.46%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.45	1.65	5.25	1.32	2.40	3.12	2.94	3.53	2.88	2.11	1.75
Quick Ratio	3.42	1.52	3.33	1.10	2.30	3.02	2.80	3.31	2.78	1.98	1.63
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-0.08	-5.48	-298	155	-16	-55	64	43	-12	120	-194
Operating Cash Flow to CapEx	-6,446.32%	-610.91%	1,325.58%	2,486.31%	2,179.15%	1,312.19%	4,143.90%	365.89%	358.01%	239.15%	649.96%
Free Cash Flow to Firm to Interest Expense	-0.12	-4.13	-5,023.72	1,946.72	-27.95	-11.58	6.71	8.02	-1.49	7.46	-5.86
Operating Cash Flow to Interest Expense	-2.18	-0.21	711.61	650.45	45.45	2.89	4.86	13.04	10.37	4.24	1.58
Operating Cash Flow Less CapEx to Interest Expense	-2.21	-0.24	604.25	624.29	43.36	2.67	4.74	9.48	7.47	2.47	1.33
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.65	2.70	4.23	0.85	1.04	0.90	0.89	0.92	1.25	1.46	1.78
Accounts Receivable Turnover	6.72	11.83	46.49	16.81	13.40	8.40	10.06	10.30	11.10	10.93	9.19
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	128.57	97.40	111.70	29.47	39.19	45.12	32.71	18.63	14.15	23.97	189.74
Accounts Payable Turnover	7.57	9.22	81.69	18.57	15.55	16.68	14.36	11.89	16.85	18.70	19.37
Days Sales Outstanding (DSO)	54.32	30.86	49.02	21.71	27.23	43.45	36.29	35.43	32.90	33.39	39.70
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	48.21	39.59	51.41	19.66	23.47	21.88	25.42	30.70	21.66	19.52	18.84
Cash Conversion Cycle (CCC)	6.11	-8.73	6.77	2.05	3.76	21.57	10.87	4.73	11.24	13.87	20.86
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-2.53	2.46	319	197	277	354	345	360	427	361	610
Invested Capital Turnover	-8.70	-905.47	7.54	1.38	2.20	1.78	1.97	2.19	2.91	3.52	4.19
Increase / (Decrease) in Invested Capital	-2.66	4.99	634	-123	80	77	-8.68	15	67	-66	249
Enterprise Value (EV)	29	8.72	91	725	836	1,134	1,011	0.00	0.00	0.00	0.00
Market Capitalization	29	3.18	36	688	753	972	997	0.00	0.00	0.00	0.00
Book Value per Share	($0.03)	($0.06)	$29.28	$26.51	$5.30	$5.49	$6.10	$8.07	$9.57	$10.54	$12.67
Tangible Book Value per Share	($0.05)	($0.13)	($20.87)	($22.12)	($2.70)	($4.30)	$0.09	$2.14	$3.47	$4.53	$3.12
Total Capital	4.68	7.74	501	338	407	603	686	694	763	689	949
Total Debt	6.31	8.73	0.29	1.23	0.56	242	241	184	204	278	435
Total Long-Term Debt	6.31	7.69	0.00	0.62	0.52	232	230	183	203	259	425
Net Debt	-0.54	3.72	-100	-140	-143	-7.45	-100	-145	-132	-50	96
Capital Expenditures (CapEx)	0.02	0.04	6.61	2.08	1.17	1.04	1.11	19	23	29	8.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.87	-0.09	-28	-84	-7.14	13	-27	4.01	-13	-34	-8.57
Debt-free Net Working Capital (DFNWC)	5.98	4.92	61	35	101	233	234	291	280	262	282
Net Working Capital (NWC)	5.98	3.89	61	35	101	224	224	290	280	243	273
Net Nonoperating Expense (NNE)	1.82	0.86	-0.72	-13	4.23	4.50	-67	12	9.32	-3.36	5.27
Net Nonoperating Obligations (NNO)	-0.91	3.45	-100	-140	-130	-7.18	-100	-151	-132	-49	96
Total Depreciation and Amortization (D&A)	0.42	0.86	36	19	19	19	20	19	18	19	30
Debt-free, Cash-free Net Working Capital to Revenue	-8.29%	-0.27%	-21.70%	-23.50%	-1.37%	2.38%	-3.88%	0.52%	-1.18%	-2.45%	-0.42%
Debt-free Net Working Capital to Revenue	57.06%	14.93%	38.69%	9.87%	19.40%	41.59%	34.12%	37.54%	24.48%	18.92%	13.87%
Net Working Capital to Revenue	57.06%	11.78%	23.89%	9.70%	19.40%	39.89%	32.54%	37.44%	24.43%	17.51%	13.41%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($1.33)	$0.00	$0.33	$0.41	$1.04	$1.69	$0.00	$1.30	$0.91
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	30.42M	0.00	32.89M	34.71M	36.53M	55.96M	0.00	55.42M	56.25M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($1.38)	$0.00	$0.29	$0.39	$1.01	$1.63	$0.00	$1.29	$0.90
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	5.75M	0.00	37.91M	36.40M	37.45M	55.96M	0.00	55.42M	56.25M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($1.79)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	10.43M	0.00	35.80M	52.80M	54.59M	55.96M	0.00	55.42M	56.25M
Normalized Net Operating Profit after Tax (NOPAT)	-2.74	-0.49	6.39	35	67	24	55	58	55	54	55
Normalized NOPAT Margin	-26.10%	-1.47%	4.18%	9.72%	12.94%	4.20%	8.02%	7.51%	4.81%	3.93%	2.71%
Pre Tax Income Margin	-43.30%	-3.59%	12.31%	13.95%	15.89%	4.61%	25.97%	10.05%	7.57%	6.48%	3.97%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-5.68	0.11	221.54	454.15	160.52	7.49	8.59	15.51	10.98	5.35	2.87
NOPAT to Interest Expense	-4.03	-0.37	302.86	406.56	114.98	4.68	5.80	10.78	6.95	3.38	1.67
EBIT Less CapEx to Interest Expense	-5.72	0.07	335.72	427.99	158.44	7.27	8.47	11.95	8.08	3.58	2.63
NOPAT Less CapEx to Interest Expense	-4.06	-0.40	141.81	380.39	112.89	4.46	5.68	7.22	4.06	1.61	1.43
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-5.26%	-44.51%	509.69%	22.80%	29.42%	349.06%	42.89%	70.59%	40.75%	107.44%	7.86%
Augmented Payout Ratio	-5.26%	-44.51%	520.02%	29.73%	37.80%	424.55%	43.33%	84.63%	60.97%	131.85%	9.74%

This table displays calculated financial ratios and metrics derived from Astrana Health's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	39.58%	50.80%	28.10%	29.11%	9.83%	19.90%	39.65%	37.49%
EBITDA Growth	2,015.78%	190.32%	-3.38%	58.76%	-3.90%	49.74%	29.65%	-16.29%
EBIT Growth	676.82%	150.10%	-3.79%	75.67%	-3.32%	56.89%	24.06%	-24.82%
NOPAT Growth	-22.04%	-167.46%	-12.38%	43.84%	-0.86%	47.08%	37.36%	-30.03%
Net Income Growth	543.77%	96.08%	9.07%	55.02%	17.06%	35.03%	25.08%	-32.15%
EPS Growth	-32.43%	-135.00%	-6.67%	7.69%	-6.00%	10.71%	42.86%	-29.79%
Operating Cash Flow Growth	-170.01%	796.79%	-67.88%	186.02%	142.95%	-22.58%	0.00%	0.00%
Free Cash Flow Firm Growth	-907.55%	-421.18%	-96.89%	71.22%	119.87%	116.51%	-287.15%	-215.27%
Invested Capital Growth	48.47%	18.98%	15.15%	9.00%	0.43%	3.06%	23.57%	10.13%
Revenue Q/Q Growth	17.54%	-7.19%	14.63%	3.25%	-0.01%	0.00%	20.26%	-1.55%
EBITDA Q/Q Growth	122.32%	-68.47%	46.57%	54.55%	34.57%	0.00%	33.82%	-13.12%
EBIT Q/Q Growth	153.84%	-74.97%	63.42%	69.18%	39.71%	0.00%	33.78%	-15.34%
NOPAT Q/Q Growth	178.10%	-103.66%	1,454.89%	4.24%	91.66%	0.00%	-2.65%	-2.37%
Net Income Q/Q Growth	111.91%	-103.70%	1,514.27%	39.99%	60.01%	0.00%	29.68%	-13.19%
EPS Q/Q Growth	92.31%	-114.00%	500.00%	0.00%	67.86%	0.00%	29.03%	-17.50%
Operating Cash Flow Q/Q Growth	-497.63%	336.80%	-90.91%	234.22%	-40.30%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	-76.44%	48.17%	35.44%	51.25%	221.82%	0.00%	-1,243.46%	63.73%
Invested Capital Q/Q Growth	21.88%	-14.15%	5.02%	-0.80%	12.30%	0.00%	18.93%	0.09%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	24.05%	13.97%	14.19%	15.89%	20.91%	18.29%	15.11%	15.35%
EBITDA Margin	14.82%	5.04%	6.44%	9.64%	12.97%	8.04%	8.95%	7.90%
Operating Margin	15.80%	4.28%	6.63%	7.76%	11.23%	7.45%	6.18%	5.94%
EBIT Margin	13.25%	3.57%	5.10%	8.35%	11.67%	6.67%	7.42%	6.38%
Profit (Net Income) Margin	7.54%	-0.30%	3.70%	5.02%	8.03%	4.17%	4.50%	3.97%
Tax Burden Percent	57.91%	-8.44%	64.34%	55.51%	73.58%	70.25%	68.55%	70.79%
Interest Burden Percent	98.22%	99.43%	112.94%	108.32%	93.59%	89.03%	88.43%	87.80%
Effective Tax Rate	42.09%	108.44%	35.66%	44.49%	26.42%	29.75%	31.45%	29.21%
Return on Invested Capital (ROIC)	22.90%	-1.05%	12.37%	13.06%	21.93%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	26.99%	-1.18%	13.86%	11.11%	22.86%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-6.22%	0.31%	-3.24%	-2.54%	-3.30%	0.00%	0.00%	0.00%
Return on Equity (ROE)	16.68%	-0.74%	9.13%	10.52%	18.63%	0.00%	0.00%	0.00%
Cash Return on Invested Capital (CROIC)	-28.93%	-3.37%	-1.35%	4.91%	11.17%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	15.26%	4.46%	6.50%	10.95%	15.36%	0.00%	0.00%	0.00%
Return on Assets (ROA)	8.68%	-0.37%	4.72%	6.58%	10.58%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	14.55%	-0.69%	8.51%	9.92%	17.60%	0.00%	0.00%	0.00%
Return on Equity Simple (ROE_SIMPLE)	4.72%	0.00%	8.53%	9.36%	9.61%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	29	-1.06	14	15	29	21	21	20
NOPAT Margin	9.15%	-0.36%	4.27%	4.31%	8.26%	5.24%	4.24%	4.20%
Net Nonoperating Expense Percent (NNEP)	-4.09%	0.13%	-1.49%	1.95%	-0.93%	-8.28%	3.89%	-3.28%
Cost of Revenue to Revenue	75.95%	86.03%	85.81%	84.11%	79.09%	81.71%	84.89%	84.65%
SG&A Expenses to Revenue	6.75%	8.31%	6.28%	6.91%	8.45%	9.58%	7.39%	7.90%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	8.25%	9.69%	7.55%	8.13%	9.68%	10.84%	8.92%	9.41%
Earnings before Interest and Taxes (EBIT)	42	11	17	29	41	27	36	31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	47	15	22	34	45	33	44	38
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.53	3.13	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	10.02	8.64	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.72	1.49	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	31.18	37.62	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.21%	2.66%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.58	3.70	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	1.71	1.39	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	24.10	15.03	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	32.26	18.23	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	42.48	28.78	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	19.30	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.37	0.37	0.37	0.36	0.34	0.86	0.92	0.86
Long-Term Debt to Equity	0.36	0.36	0.36	0.35	0.34	0.82	0.89	0.83
Financial Leverage	-0.23	-0.26	-0.23	-0.23	-0.14	-0.10	-0.06	-0.06
Leverage Ratio	1.67	1.71	1.74	1.78	1.73	2.19	2.15	2.10
Compound Leverage Factor	1.64	1.71	1.97	1.93	1.61	1.95	1.90	1.84
Debt to Total Capital	26.77%	26.75%	26.78%	26.35%	25.36%	46.31%	48.01%	46.35%
Short-Term Debt to Total Capital	0.42%	0.08%	0.08%	0.33%	0.36%	2.46%	1.85%	1.59%
Long-Term Debt to Total Capital	26.36%	26.67%	26.69%	26.02%	25.00%	43.85%	46.16%	44.76%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	5.68%	2.10%	2.20%	2.22%	2.66%	-23.86%	-21.74%	-20.90%
Common Equity to Total Capital	67.55%	71.15%	71.02%	71.43%	71.98%	77.55%	73.73%	74.54%
Debt to EBITDA	2.73	1.94	1.98	1.78	1.82	0.00	0.00	0.00
Net Debt to EBITDA	-0.74	-1.24	-1.11	-1.18	-1.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	2.68	1.93	1.97	1.76	1.79	0.00	0.00	0.00
Debt to NOPAT	4.81	3.71	3.86	3.61	3.60	0.00	0.00	0.00
Net Debt to NOPAT	-1.30	-2.38	-2.17	-2.38	-1.98	0.00	0.00	0.00
Long-Term Debt to NOPAT	4.73	3.69	3.85	3.56	3.55	0.00	0.00	0.00
Altman Z-Score	4.68	4.33	0.00	0.00	0.00	0.00	0.00	0.00
Noncontrolling Interest Sharing Ratio	12.79%	7.34%	6.81%	5.72%	5.54%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	2.84	2.88	2.62	2.50	2.35	1.52	1.84	1.91
Quick Ratio	2.69	2.78	2.50	2.42	2.28	1.47	1.71	1.79
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-134	-69	-45	-22	27	7.40	-85	-31
Operating Cash Flow to CapEx	-1,117.79%	9,586.79%	128.09%	227.53%	375.27%	1,619.78%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-55.29	-26.99	-13.71	-6.01	7.04	0.98	-9.85	-3.46
Operating Cash Flow to Interest Expense	-14.81	33.04	2.36	7.10	4.08	0.79	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-16.14	32.69	0.52	3.98	2.99	0.74	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	1.15	1.25	1.27	1.31	1.32	0.00	0.00	0.00
Accounts Receivable Turnover	7.45	11.10	8.18	8.29	6.87	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	13.62	14.15	13.26	12.29	11.41	0.00	0.00	0.00
Accounts Payable Turnover	14.37	16.85	17.93	17.29	19.61	0.00	0.00	0.00
Days Sales Outstanding (DSO)	48.99	32.90	44.61	44.05	53.15	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	25.41	21.66	20.35	21.11	18.61	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	23.58	11.24	24.26	22.94	34.54	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	499	428	450	446	501	464	551	552
Invested Capital Turnover	2.50	2.90	2.90	3.03	2.66	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	163	68	59	37	2.15	14	105	51
Enterprise Value (EV)	1,788	1,585	0.00	0.00	0.00	0.00	0.00	0.00
Market Capitalization	1,800	1,700	0.00	0.00	0.00	0.00	0.00	0.00
Book Value per Share	$9.04	$9.57	$9.55	$9.84	$10.32	$11.79	$12.12	$12.53
Tangible Book Value per Share	$3.18	$3.47	$3.50	$3.78	$4.24	$2.23	$2.73	$3.31
Total Capital	756	763	772	792	825	843	921	945
Total Debt	202	204	207	209	209	390	442	438
Total Long-Term Debt	199	203	206	206	206	369	425	423
Net Debt	-55	-131	-116	-138	-115	11	72	44
Capital Expenditures (CapEx)	3.21	0.89	6.03	11	4.11	0.37	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	73	-13	3.33	-16	-0.70	-133	-50	-51
Debt-free Net Working Capital (DFNWC)	291	280	282	282	276	204	278	299
Net Working Capital (NWC)	287	280	281	279	273	184	261	284
Net Nonoperating Expense (NNE)	5.11	-0.18	1.91	-2.48	0.79	4.31	-1.26	1.14
Net Nonoperating Obligations (NNO)	-54	-130	-115	-137	-114	11	73	45
Total Depreciation and Amortization (D&A)	4.98	4.30	4.53	4.49	4.54	5.55	7.44	7.26
Debt-free, Cash-free Net Working Capital to Revenue	7.01%	-1.18%	0.27%	-1.25%	-0.05%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	27.81%	24.48%	23.15%	21.74%	20.81%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	27.50%	24.43%	23.10%	21.54%	20.58%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.58	($0.10)	$0.00	$0.28	$0.47	$0.31	$0.40	$0.34
Adjusted Weighted Average Basic Shares Outstanding	56.72M	57.44M	0.00	57.56M	46.55M	56.03M	56.21M	56.25M
Adjusted Diluted Earnings per Share	$0.56	($0.07)	$0.00	$0.28	$0.47	$0.31	$0.40	$0.33
Adjusted Weighted Average Diluted Shares Outstanding	56.72M	57.44M	0.00	57.56M	46.92M	56.03M	56.21M	56.25M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	56.72M	57.44M	0.00	57.56M	58.28M	56.03M	56.21M	56.25M
Normalized Net Operating Profit after Tax (NOPAT)	29	8.81	14	15	29	21	21	20
Normalized NOPAT Margin	9.15%	2.99%	4.27%	4.31%	8.26%	5.24%	4.24%	4.20%
Pre Tax Income Margin	13.02%	3.55%	5.76%	9.04%	10.92%	5.94%	6.56%	5.60%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	17.35	4.09	5.26	8.00	10.75	3.55	4.20	3.45
NOPAT to Interest Expense	11.98	-0.41	4.40	4.13	7.61	2.79	2.40	2.27
EBIT Less CapEx to Interest Expense	16.02	3.75	3.41	4.88	9.66	3.51	0.00	0.00
NOPAT Less CapEx to Interest Expense	10.65	-0.76	2.56	1.01	6.52	2.74	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	58.28%	40.75%	37.67%	13.14%	14.54%	0.00%	0.00%	0.00%
Augmented Payout Ratio	101.37%	60.97%	77.34%	30.71%	30.82%	0.00%	0.00%	0.00%

Frequently Asked Questions About Astrana Health's Financials

When does Astrana Health's fiscal year end?

According to the most recent income statement we have on file, Astrana Health's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Astrana Health's net income changed over the last 10 years?

Astrana Health's net income appears to be on an upward trend, with a most recent value of $49.93 million in 2024, falling from -$4.56 million in 2014. The previous period was $57.85 million in 2023. View Astrana Health's forecast to see where analysts expect Astrana Health to go next.

What is Astrana Health's operating income?

Astrana Health's total operating income in 2024 was $89.35 million, based on the following breakdown:

Total Gross Profit: $271.39 million
Total Operating Expenses: $182.04 million

How has Astrana Health revenue changed over the last 10 years?

Over the last 10 years, Astrana Health's total revenue changed from $10.48 million in 2014 to $2.03 billion in 2024, a change of 19,305.6%.

How much debt does Astrana Health have?

Astrana Health's total liabilities were at $840.73 million at the end of 2024, a 60.9% increase from 2023, and a 7,469.7% increase since 2014.

How much cash does Astrana Health have?

In the past 10 years, Astrana Health's cash and equivalents has ranged from $5.01 million in 2015 to $293.81 million in 2023, and is currently $288.46 million as of their latest financial filing in 2024.

How has Astrana Health's book value per share changed over the last 10 years?

Over the last 10 years, Astrana Health's book value per share changed from -0.03 in 2014 to 12.67 in 2024, a change of -39,693.8%.

Related Companies

This page (NASDAQ:ASTH) was last updated on 5/6/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Astrana Health (ASTH) Financials

Frequently Asked Questions About Astrana Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Astrana Health (ASTH) Financials

Annual Income Statements for Astrana Health

Quarterly Income Statements for Astrana Health

Annual Cash Flow Statements for Astrana Health

Quarterly Cash Flow Statements for Astrana Health

Annual Balance Sheets for Astrana Health

Quarterly Balance Sheets for Astrana Health

Annual Metrics and Ratios for Astrana Health

Quarterly Metrics and Ratios for Astrana Health

Frequently Asked Questions About Astrana Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools